Lercanidipina Jaba

Lercanidipine, the active ingredient in Lercanidipina Jaba, is a calcium channel blocker presented as an oral pharmaceutical product for oral use. It is employed to manage elevated blood pressure in adult patients diagnosed with hypertension. GNH USA supplies Lercanidipina Jaba as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is indicated for the treatment of hypertension, acting on the vascular smooth‑muscle calcium channels to lower blood pressure. - Essential hypertension: reduces systolic and diastolic pressure in patients with primary high blood pressure. - Isolated systolic hypertension: effectively lowers elevated systolic readings, especially in older adults. - Hypertension in patients with diabetes: helps control blood pressure without adversely affecting glucose metabolism.

Lercanidipine may be associated with several adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of ankles or feet. - Dizziness: especially upon standing. - Tachycardia: increased heart rate. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of face, lips, tongue or throat. - Hepatic dysfunction: abnormal liver enzyme elevations. - Myocardial infarction: rare occurrence in susceptible individuals.

When prescribing Lercanidipina Jaba, clinicians should consider several safety aspects. - Cardiovascular monitoring: assess blood pressure and heart rate regularly. - Concomitant antihypertensives: adjust doses to avoid excessive hypotension. - Liver impairment: use with caution in patients with hepatic dysfunction. - Elderly patients: start at lower doses due to increased sensitivity. - Pregnancy and lactation: avoid unless clearly needed, after risk‑benefit evaluation. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels, risking toxicity. - Grapefruit juice: can elevate drug concentration, leading to excessive hypotension.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives (e.g., ACE inhibitors, diuretics): may enhance blood‑pressure lowering effect. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Beta‑blockers: combined use may cause additive bradycardia.